慢性丙型肝炎患者颈动脉内膜和血清内脏脂肪素的变化

doi:10.3969/j.issn.1672-5069.2015.06.029

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (6): 674-675.doi: 10.3969/j.issn.1672-5069.2015.06.029

慢性丙型肝炎患者颈动脉内膜和血清内脏脂肪素的变化

苏少慧，刘颖娇，郭兆霞，胡义亭，侯洪涛，张建，焦荣红，王玉珍

050051 石家庄市河北省人民医院消化科（苏少慧,刘颖娇,郭兆霞,胡义亭,侯洪涛,张建,王玉珍）; 功能科（焦荣红）

收稿日期:2015-05-14 出版日期:2015-11-20 发布日期:2016-02-04
作者简介:苏少慧,女,54岁,教授,主任医师。E-mail :sshui2828@126.com

Relationship between plasma visfatin and carotid artery atherosclerosis in patients with hepatitis C

Su Shaohui， Liu Yingjiao， Guo Zhaoxia， et al.

Department of Degestive Diseases,General Hospital,Shijiazhuang 050051,Hebei Province, China

Received:2015-05-14 Online:2015-11-20 Published:2016-02-04

摘要/Abstract

摘要： 目的调查慢性丙型肝炎患者颈动脉内中膜厚度、斑块形成和血清内脏脂肪素（Visfatin）的关系。方法使用彩色多普勒超声检测46例慢性丙型肝炎患者和40例健康人颈动脉内膜中膜厚度和斑块形成,采用ELISA法检测血清Visfatin、C反应蛋白和GGT水平。结果慢性丙型肝炎患者颈动脉内中膜厚度为（1.21±0.36） mm,显著高于对照组[（0.83±0.31） mm,P<0.05];慢性丙型肝炎患者颈动脉斑块发生率为32.6%,显著高于对照组（10 %,P<0.05）;慢性丙型肝炎患者血清Visfatin水平为（42.89±18.63） μg/L,显著高于对照组[（27.02±13.14） μg/L,P<0.05];20例颈动脉内中膜增厚的慢性丙型肝炎患者血清Visfatin水平为（55.06±15.72） μg/L,显著高于26例内膜不增厚者[（33.54±15.09）μg/L,t=-4.710,P<0.05],差异有统计学意义;15例存在颈动脉斑块的慢性丙型肝炎患者血清HCV RNA水平为（5.78±1.56） logl0拷贝/毫升,较31例无斑块患者[（3.84±0.97） log10拷贝/毫升]明显增高（Z=-3,972,P<0.05）,差异有统计学意义。结论慢性丙型肝炎患者颈动脉内中膜增厚,颈动脉斑块发生率明显增高,与血清高水平的Visfatin和HCV RNA可能存在关系。

关键词: 慢性丙型肝炎, 内脏脂肪素, 颈动脉内膜中膜厚度, 颈动脉斑块

Key words: Hepatitis C, Intima-metia thickness, Visfatin, Carotid artery atherosclerosis

苏少慧，刘颖娇，郭兆霞，胡义亭，侯洪涛，张建，焦荣红，王玉珍. 慢性丙型肝炎患者颈动脉内膜和血清内脏脂肪素的变化[J]. 实用肝脏病杂志, 2015, 18(6): 674-675.

Su Shaohui， Liu Yingjiao， Guo Zhaoxia， et al.. Relationship between plasma visfatin and carotid artery atherosclerosis in patients with hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 674-675.

参考文献

[1] Petta S,Torres D,Fazio G,et al. Carotid atherosclerosis and chronic hepatitis C:a prospective study of risk associations. Hepatology,2012,55（5）:1317-1323.
[2] Zampino R,Marrone A,Restivo L,et al. Chronic HCV infection and inflammation:Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol,2013,5（10）:528-540.
[3] 中华医学会肝病学分会和传染病与寄生虫病学分会.丙型肝炎防治指南. 中华肝脏病杂志,2004,12（4）:194-198.
[4] Ebrahim S,Papacosta O,Whincup P,et al. Carotid plaque,intimametia thickness,cardiovescular risk factors,and prevalent cardiovescular diseases in men and women:the British Regional Heart Study. Stroke,1999,30（4）:841-850.
[5] Mencin A,Kluwe J,Schwabe RF. Toll-like receptors as tagets in chronic liver diseases. Gut,2009,58（5）:704-720.
[6] Sandler NG,Koh C,Roque A,et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology,2011,141（4）:1220-1230.
[7] Dahl TB,Yndestad A,Skjelland M,et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization. Circulation,2007,115（8）:972-980.
[8] Zhong M,Tan HW,Gong HP,et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol （ Oxf）,2008,69（6）:878-884.
[9] Zampino R,Marrone A,Restivo L,et al. Chronic HCV infection and inflammation:Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol,2013,5（10）:528-540.
[10] Alyan O,Kacmaz F,Ozdemir O,et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J,2008,72（12）:1960-1965.
[11] Aksakal E,Tanboga IH,Kurt M,et al. The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis,2012,221（2）:596-601.
[12] Shabbir S,Khan FA. Serum gamma glutamyltransferase:a novel biomarker for screening of premature coronary artery disease. Cardiovasc Revasc Med ,2011,12（6）:367-374.
[13] Du G,Song Z,Zhang Q. Gammaglutamyl transferase is associated with cardiovascular and all-cause mortality:a meta-analysis of prospective cohort studies. Prev Med,2013,57(1):31-37.
[14] Franzini M,Corti A,Martinelli B,et al. Cammaglutamyl transferase activity in human atherosclerotic plaques biochemical similarities with the circulating enzyme. Atherosclerosis,2009,202（1）:119-127.
[15] Boddi M,Abbate R,Chellini B,et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol,2010,47(1): 72-75.
[16] Matsumori A,Shimada T,Chapman NM,et al. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail,2006,12（4）:293-298.
[17] Boddi M,Abbate R,Chellini B,et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis, 2007,39(1):S55-S60.
[18] Luigi E,Adinolfi E,Luciano R,et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV related steatosis. Atherosclerosis,2012,221（2）:496-502.

慢性丙型肝炎患者颈动脉内膜和血清内脏脂肪素的变化

Relationship between plasma visfatin and carotid artery atherosclerosis in patients with hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[2]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[3]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[4]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[5]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[6]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[7]	侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.
[8]	周思思, 沈有秀, 李娟, 俞科贤. 慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 689-692.
[9]	曹风华, 经继生, 赵伟, 江英骙, 马洁. 大剂量普通α-干扰素与聚乙二醇化α-干扰素联合利巴韦林治疗慢性丙型肝炎患者临床疗效及安全性比较研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 729-732.
[10]	王婧婧, 张瑜, 董娜, 韩振坤, 翟景明. 慢性丙型肝炎外周血miR-1273g-3p水平变化及其诊断肝纤维化分期的效能分析*[J]. 实用肝脏病杂志, 2018, 21(3): 401-404.
[11]	焦方舟, 张海月, 张文斌, 王鲁文, 龚作炯. 索非布韦联合α-干扰素治疗慢性丙型肝炎患者疗效比较的Meta分析[J]. 实用肝脏病杂志, 2018, 21(2): 220-224.
[12]	陶国运, 艾莉莎, 张丽. 利巴韦林血药浓度监测对基因1b型慢性丙型肝炎患者治疗效果的预测价值分析[J]. 实用肝脏病杂志, 2018, 21(2): 287-288.
[13]	段军民, 李素森, 刘丽珍, 雷鹏, 于天威, 唐瑞娟. 聚乙二醇干扰素α-2a与普通干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者疗效比较和影响疗效的预测因素分析[J]. 实用肝脏病杂志, 2018, 21(1): 64-67.
[14]	居朝霞, 吴桂香, 张波. 院外延伸性护理对慢性丙型肝炎患者负性情感和自我效能的正性作用研究*[J]. 实用肝脏病杂志, 2017, 20(6): 701-704.
[15]	娜丽. 慢性丙型肝炎患者外周血IL-28B基因型多态性及其对持续病毒学应答的影响[J]. 实用肝脏病杂志, 2017, 20(5): 600-601.